Scholarlink

Patients (both individual patients and patient organisations) are key experts at all steps of medicinal product evaluation. The French National Authority for Health considers patients as essential actors of HTA and provides these experts with specific training. This chapter outlines the processes for appraisal of clinical effectiveness of medicines in France and the evolution of patient participation therein. It is anticipated that the role of patients will progressively increase in areas such as clinical trial methodology, health economics, and public health. Success in this evolution requires a careful balance between patient advocacy and scientific rigor, while ensuring independence of various stakeholders.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Discussion: Perspective of an HTA Appraisal Committee Chair in France

  • 章节

  • 出版模式：

    开放获取

  • 发表日期：

    2026年

查看全文
  • Pierre Cochat

摘要

Patients (both individual patients and patient organisations) are key experts at all steps of medicinal product evaluation. The French National Authority for Health considers patients as essential actors of HTA and provides these experts with specific training. This chapter outlines the processes for appraisal of clinical effectiveness of medicines in France and the evolution of patient participation therein. It is anticipated that the role of patients will progressively increase in areas such as clinical trial methodology, health economics, and public health. Success in this evolution requires a careful balance between patient advocacy and scientific rigor, while ensuring independence of various stakeholders.